StockCIK 1211583
FENNEC PHARMACEUTICALS INC. (FENC): Insider Trades and Fund Holdings
In the past 12 months, FENNEC PHARMACEUTICALS INC. insiders reported 0 open-market purchases worth $0 and 4 sales worth $1.31M; 3 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$1.31MSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 16, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 16 | Marco Maria BrugheraDirector | ▼ SELL10b5-1 | $160K |
| Sep 1 | Rosty RaykovOther | ▼ SELL10b5-1 | $121K |
| Aug 31 | Pierre Sargis SayadChief Medical Officer | ▼ SELL | $146K |
| Aug 28 | Robert AndradeCFO | ▼ SELL10b5-1 | $884K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Marco Maria Brughera | Director | 0 | $0 | 1 | $160K |
| Rosty Raykov | Other | 0 | $0 | 1 | $121K |
| Pierre Sargis Sayad | Chief Medical Officer | 0 | $0 | 1 | $146K |
| Robert Andrade | CFO | 0 | $0 | 1 | $884K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report FENC
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 134,200 | $1.44M | ▲ New |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →